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and confers an adverse prognosis.
OBJECTIVES This study aimed to determine whether the efficacy and safety of a therapeutic strategy involving
low-dose intracoronary alteplase infused early after coronary reperfusion associates with ischemic time.
METHODS This study was conducted in a prospective, multicenter, parallel group, 1:1:1 randomized, dose-ranging trial
in patients undergoing primary percutaneous coronary intervention. Ischemic time, defined as the time from symptom
onset to coronary reperfusion, was a pre-specified subgroup of interest. Between March 17, 2016, and December 21,
2017, 440 patients, presenting with ST-segment elevation myocardial infarction within 6 h of symptom onset
(<2 h, n ¼ 107; $2 h but <4 h, n ¼ 235; $4 h to 6 h, n ¼ 98), were enrolled at 11 U.K. hospitals. Participants were
randomly assigned to treatment with placebo (n ¼ 151), alteplase 10 mg (n ¼ 144), or alteplase 20 mg (n ¼ 145). The
primary outcome was the amount of microvascular obstruction (MVO) (percentage of left ventricular mass) quantified by
cardiac magnetic resonance imaging at 2 to 7 days (available for 396 of 440).
RESULTS Overall, there was no association between alteplase dose and the extent of MVO (p for trend ¼ 0.128).
However, in patients with an ischemic time $4 to 6 h, alteplase increased the mean extent of MVO compared with
placebo: 1.14% (placebo) versus 3.11% (10 mg) versus 5.20% (20 mg); p ¼ 0.009 for the trend. The interaction between
ischemic time and alteplase dose was statistically significant (p ¼ 0.018).
CONCLUSION In patients presenting with ST-segment elevation myocardial infarction and an ischemic time $4 to 6 h,
adjunctive treatment with low-dose intracoronary alteplase during primary percutaneous coronary intervention was
associated with increased MVO. Intracoronary alteplase may be harmful for this subgroup. (A Trial of Low-Dose
Adjunctive Alteplase During Primary PCI [T-TIME]; NCT02257294) (J Am Coll Cardiol 2020;75:1406–21)
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1407AB BR E V I A T I O N S
AND ACRONYM S
AUC = area under the curve
CMR = cardiac magnetic
resonance
IQR = interquartile range
MI = myocardial infarction
MVO = microvascular
obstruction
OR = odds ratio
PPCI = primary percutaneous
coronary intervention
STEMI = ST-segment elevation
myocardial infarction
TIMI = Thrombolysis In
ardial InfarctionP rimary percutaneous coronary intervention(PPCI) to emergently reopen the occluded coro-nary artery, restore blood flow, and secure
vessel patency with a stent is the evidence-based stan-
dard of care for ST-segment elevation myocardial
infarction (STEMI) (1). However, the success of PPCI
is limited by failed microvascular reperfusion, which
occurs in one-half of all treated patients (2,3). This
complication, described as microvascular obstruction
(MVO), is associated with adverse left ventricular
remodeling and reduced left ventricular function and
is independently predictive of cardiac prognosis (4).
During PPCI, distal embolization of thrombus within
the lumen of the infarct-related coronary artery and
microvascular thrombosis (5–9), notably of fibrin-rich
microthrombi (6), contribute to MVO. Myocardial
hemorrhage is closely related to MVO (3) and occurs
when endothelial cell injury compromises capillary
integrity leading to the extravasation of blood into
the extracellular space. T2*-weighted cardiacmagnetic
resonance (CMR) is the established method to identify
and evaluate myocardial hemorrhage in vivo, accumu-
lation of paramagnetic hemoglobin breakdown prod-
ucts leads to a shortening of T2* relaxation times,
resulting in a hypointense zone on imaging that repre-
sents tissue hemorrhage (9,10). Late gadolinium-
enhanced CMR imaging is used to identify MVO, a
dark area representing failed perfusion at the core of
the bright infarct. Validation in swine established
that the hypointense core on T2* imaging corresponds
with severe capillary loss and destruction resulting in
tissue hemorrhage, with excellent anatomical correla-
tion between the localization and extent of MVO and
myocardial hemorrhage (9).SEE PAGE 1422Fibrinolytic therapy is an effective treatment for
acute coronary thrombosis (11). A facilitated PCI strat-
egy involving full- or half-dose adjunctive fibrinolytic
therapy given before PCI with stenting improves cor-
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plase and timely PCI improves epicardial and
myocardial flow when compared with PPCI
alone. However, combination-facilitated PCI
involving either full-dose (14) or half-dose
lytic therapy (15) causes paradoxical activa-
tion of thrombin, clot formation, and bleeding.
In T-TIME (A Trial of Low-Dose Adjunctive
Alteplase During Primary PCI), we hypothe-
sized that a therapeutic strategy involving
low-dose intracoronary fibrinolytic therapy
with alteplase infused early after coronary
reperfusion would reduce MVO. Patients with
acute STEMI presenting <6 h after symptom
onset and a large thrombus burden evident at
initial coronary angiographywere enrolled in a
3-arm dose-ranging design (10 or 20 mg of alteplase or
placebo). The primary analysis determined that alte-
plase did not reduce the amount of MVO revealed by
CMR imaging 2 to 7 days post-MI (primary outcome)
and the secondary outcomes were consistent with this
result (16).
Infarct size is influenced by ischemic time (17), as
are the efficacies of primary reperfusion therapies,
including systemic fibrinolysis (18) and primary PCI
(19). In this pre-specified analysis, we hypothesized
that the effects of adjunctive intracoronary adminis-
tration of low-dose alteplase during PPCI could be
associated with ischemic time. We assessed the as-
sociations among ischemic time, treatment
group (placebo, alteplase 10 mg, alteplase 20 mg), and
the primary and secondary outcomes in this clinical
trial.
METHODS
TRIAL DESIGN. We performed a randomized, double-
blind, placebo-controlled, parallel group phase 2
clinical trial of low-dose adjunctive alteplase during
PPCI, the main results of which have been published
previously (16).
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1408PARTICIPANTS AND ELIGIBILITY CRITERIA. Patients
with a clinical diagnosis of acute STEMI with a
symptom onset to reperfusion time of 6 h or less were
eligible for randomization. Radial artery access was
required, angiographic criteria included a proximal-
mid coronary artery occlusion (TIMI [Thrombolysis
In Myocardial Infarction] flow grade 0/1) or impaired
coronary flow (TIMI flow grade 2) in the presence of
definite angiographic evidence of thrombus (TIMI
flow grade 2þ) in a major coronary artery. Exclusion
criteria included any contraindication to fibrinolysis
or CMR and lack of informed consent. Full inclusion
and exclusion criteria are described in the
Supplemental Appendix.
SETTING. The participants were enrolled in 11 hos-
pitals in the United Kingdom and guideline-based
medical and invasive management was recom-
mended (1). Enrollment started on March 17, 2016,
and ended on December 21, 2017.
INFORMED CONSENT AND STUDY PROTOCOL.
Screening, witnessed verbal informed consent, study
drug administration, and acute assessments of effi-
cacy took place during the standard-of-care PPCI. The
protocol is included in the Supplemental Appendix.
The trial had ethics committee approval, adhered to
Guidelines for Good Clinical Practice in Clinical Trials
(20), and complied with the Declaration of Hel-
sinki (21).
RANDOMIZATION, IMPLEMENTATION, AND BLINDING.
Participants were randomized by staff in the catheter
laboratory using an interactive voice response–based
randomization system. The randomization sequence
was created using the method of randomized
permuted blocks of length 6, with stratification by
location of STEMI and study site. The allocation
sequence was on a 1:1:1 basis among the placebo and
alteplase (10 mg, 20 mg) groups and the sequence was
concealed electronically. The participants, staff, and
researchers were blinded to the treatment
group allocation.
STANDARD CARE. PPCI followed contemporary
practice guidelines (1) (Supplemental Appendix).
INTERVENTIONS. After successful reperfusion of the
infarct-related artery, the participants immediately
received the allocated intervention. The study drug
(placebo, alteplase 10 mg, or alteplase 20 mg) was
manually infused before stent implantation. Further
details are provided in the Supplemental Appendix.
OUTCOMES. Primary outcome. The primary outcome
was the amount of MVO (percentage of left ventric-
ular mass) revealed by late gadolinium-enhanced
CMR 10 to 15 min after administration ofgadolinium-based contrast media. CMR at 1.5-T was
scheduled during the index hospitalization, 2 to
7 days after enrollment. MVO was defined as a dark
zone on early gadolinium enhancement imaging 1, 3,
5, and 7 min post-contrast injection that remained
present within an area of late gadolinium
enhancement at 15 min. The myocardial mass of the
dark zone was quantified by manual delineation and
expressed as percentage of left ventricular mass.
Secondary outcomes. Infarct definition and size. The
presence of acute infarction was established based
on abnormalities in cine wall motion, rest first-
pass myocardial perfusion, and late gadolinium-
enhancement imaging in 2 imaging planes. The
myocardial mass of late gadolinium was quantified
using computer-assisted planimetry and the territory of
infarction was delineated using a 5-SD semi-automated
method and expressed as percentage of total left
ventricular mass.
Myocardial hemorrhage. On the T2* parametric maps,
a threshold of 20 ms was applied. A region of reduced
signal intensity within the infarcted area, with a T2*
value of <20 ms (3,22) was considered to confirm the
presence of myocardial hemorrhage. The area was
manually delineated and expressed as percentage of
left ventricular mass.
Other outcomes. Additional CMR secondary outcomes
included myocardial salvage index, left ventricular
end-diastolic volume, left ventricular end-systolic
volume, and left ventricular ejection fraction at 2 to
7 days and 3 months, these are described in the
Supplemental Appendix.
BIOCHEMISTRY. Troponin T (ng/l) area under the
curve (AUC) was measured from blood samples ob-
tained immediately before reperfusion (0 h) and then
again at 2 and 24 h.
SAFETY. Fibrinogen and other parameters of coagu-
lation and hemostasis served as surrogate measures
of bleeding and safety (23,24). These parameters were
measured in blood samples when site logistics
permitted blood sample collection. The sampling
time points were at baseline before reperfusion (0 h)
and 2 and 24 h post-reperfusion.
TRIAL COORDINATION. An independent Data and
Safety Monitoring Committee and a Trial Steering
Committee had oversight of the trial and liaised with
the sponsor. Each committee had a charter that was
established before enrollment started.
SAMPLE SIZE AND STATISTICAL METHODS. The
sample size and statistical methods are described in
detail in the Supplemental Appendix. To summarize,
outcomes were analyzed using linear or logistic
regression models. Continuous outcomes were
FIGURE 1 T-TIME Flow Diagram
Randomized, n = 440 (28.8%)
Allocation
Enrollment
Assess for eligibility, n = 1,527
Excluded, n = 1,087 (71.2%)
• Lack inclusion criteria, n = 838 (77.1%)
• Declined to participate, n = 18 (1.7%)
• Logistical reasons, n = 61 (5.6%)
• Unable to undergo CMR, n = 15 (1.4%)
• Other miscellaneous, n = 155 (14.3%)
Ischemic Time
Follow-Up
Analysis
Allocated to placebo, n = 151
CMR performed, n = 137
Analyzed primary endpoint,
n = 136
Withdrew from follow-up, n = 4
Died, n = 1
Withdrew from follow-up, n = 6
Died, n = 3
Withdrew from follow-up, n = 7
Died, n = 3
CMR performed, n = 131
Analyzed primary endpoint,
n = 129
CMR performed, n = 132
Analyzed primary endpoint,
n = 131
Allocated to alteplase 10 mg, n = 144 Allocated to alteplase 20 mg, n = 145
• ≤2 hours: n = 27
• ≥2–<4: n = 83
• ≥4–6: n = 26
• ≤2 hours: n = 40
• ≥2–<4: n = 59
• ≥4–6: n = 30
• ≤2 hours: n = 31
• ≥2–<4: n = 73
• ≥4–6: n = 27
The participants are grouped by treatment group and ischemic time. Two patients (1 randomized to placebo and 1 randomized to 10 mg alteplase) received 20 mg
alteplase because an incorrect treatment pack had been selected. Four patients were unable to complete the CMR examination meaning evaluable data for the primary
outcome was not available: placebo group (n ¼ 1); 10 mg–alteplase group (n ¼ 2); 20 mg–alteplase group (n ¼ 1). CMR ¼ cardiac magnetic resonance; T-TIME ¼ A Trial
of Low-Dose Adjunctive Alteplase During Primary PCI.
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Analyses treating randomized treatment as a 3-level
or as a 2-level categorical variable (active vs. pla-
cebo) were performed. On the assumption that any
treatment effects would manifest themselves as dose-
dependent trends, randomized treatment was
modeled as a linear trend across dose groups (0 mg,
10 mg, 20 mg) in an attempt to maximize power. The
decision to model as a linear trend across treatment
groups was made post hoc with knowledge of the
data. All models were adjusted for the location of MI(anterior/nonanterior), as per the stratification of the
randomization schedule. Models for coagulation and
hemostasis parameters included an additional
adjustment for baseline value (transformed in the
same way as the outcome measurement). Models
included ischemic time categorized in 3 groups (<2
h, $2 but <4 h, $4 to 6 h), and an interaction between
ischemic time and randomized treatment.
All tests were 2-tailed, and p values <0.05 were
considered significant. All statistical analyses were
carried out with R version 3.2.4 (R Development Core
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1410Team 2015, Vienna, Austria) (25) according to a pre-
specified statistical analysis plan. No adjustments
have been made for multiple testing in these ana-
lyses, which should be viewed as exploratory rather
than definitive.
RESULTS
On the recommendation of the Data and Safety
Monitoring Committee, recruitment was dis-
continued on December 21, 2017, based on a
pre-specified futility analysis. Specifically, the con-
ditional power for an analysis on the primary efficacy
outcome based on 40% of the randomized population
(n ¼ 267) with follow-up to 3 months was <30% in
both treatment arms. The committee noted that there
were no safety concerns. By that time, 1,527 patients
undergoing PPCI for acute STEMI had been screened
(Figure 1) and 440 patients (mean age 60.5 years, 85%
male) had been randomized (151 placebo, 144 alte-
plase 10 mg, 145 alteplase 20 mg) (Table 1 and
Supplemental Table 1). The distribution of random-
ized participants by ischemic time was as follows: <2
h, 107 (24.3%); $2 but <4 h, 235 (53.4%); $4 to 6 h, 98
(22.3%). All of the randomized participants were
included in those analyses for which they had data
available. Seventeen patients (3.9%) withdrew from
the study during follow-up.
STUDY INTERVENTION. Adjunctive study treatment
was administered to 435 patients (98.9%); 5 patients
did not receive any drug (Figure 1). Two patients (1
randomized to placebo and 1 randomized to 10 mg
alteplase) received 20 mg alteplase because an
incorrect treatment pack had been selected.
PRIMARY AND SECONDARY OUTCOMES. CMR was
performed in 400 patients (90.9%) at 2 to 7 days and
367 patients (83.4%) at 3 months. The median
(interquartile range [IQR]) times to CMR at these time
points were 4 days (IQR: 3 to 6 days) and 91 days (IQR:
86 to 97 days), respectively.
PRIMARY OUTCOME. The mean MVO (percentage of
left ventricular mass) revealed by CMR 2 to 7 days
post-STEMI (primary outcome) was 2.32  4.31% in
the placebo group, 2.61  4.49% in the 10 mg alteplase
group, and 3.48  5.83% in the 20 mg alteplase group.
A linear regression analysis of square root–
transformed MVO found no evidence of a treatment
effect (mean increase in square root–transformed
MVO per 10-mg increase in alteplase dose: 0.15; 95%
confidence interval [CI]: 0.12 to 0.42; p ¼ 0.28) (16).
There was a significant interaction between
ischemic time and randomized treatment with
respect to the primary outcome (mean increase insquare root–transformed MVO per 10-mg increase in
alteplase dose: 0.56 (95% CI: 0.21 to 0.91; p ¼ 0.009)
(Table 2). There was no evidence of a treatment effect
on the extent of MVO at 2 to 7 days for patients with
ischemic times <4 h. In those with ischemic times of
4 h or more, the amount of MVO (mean percentage of
left ventricular mass) at 2 to 7 days increased from
1.14% in those treated with placebo to 3.11% (10 mg)
and 5.20% (20 mg) in those treated with alteplase
(Central Illustration). Similar results were observed
when analyzing treatment as a 3-level or 2-level cat-
egorical variable (Table 3).
SECONDARY OUTCOMES. CMR parameters at 2 to
7 days . Although the interaction between ischemic
time and treatment in relation to the binary outcome
of the presence of any MVO did not reach statistical
significance (odds ratio [OR]: 1.84; 95% CI: 1.04 to
3.24; p ¼ 0.036; interaction p ¼ 0.076), there was a
trend toward a higher prevalence with increasing
dose in patients presenting $4 to 6 h (Table 2), but no
evidence of a treatment effect with shorter ischemic
times. A similar pattern was observed regarding
myocardial hemorrhage, with an increasing preva-
lence in those with ischemic times $4 to 6 h (OR per
10-mg increase in alteplase dose: 1.93; 95% CI: 1.09 to
3.45; p ¼ 0.025), but no significant trend with shorter
ischemic times (p value for interaction ¼ 0.044), as
well as an increasing extent of myocardial hemor-
rhage (percentage of left ventricular mass) in those
with longer ischemic times (1.74% increase per 10-mg
increase in alteplase dose; 95% CI: 0.61 to 2.87;
p ¼ 0.003) (Central Illustration), but no evidence of
treatment effects with shorter ischemic times (p for
interaction ¼ 0.038). The statistical evidence for in-
teractions was weaker when considering treatment
effects categorically (Table 3), but the general pattern
of associations was very similar, with poorer out-
comes in those treated with alteplase (particularly the
20-mg dose) when the ischemic time was $4 to 6 h.
Similar trends were observed when patients were
categorized by the location of MI, anterior and non-
anterior (Table 4).
Left ventricular ejection fraction 2 to 7 days post-
STEMI was lower in patients presenting $4 to 6 h
who were treated with alteplase (10 mg or 20 mg)
compared with in those who received placebo (mean
difference: 5.0%; 95% CI: 8.6% to 1.4%;
p ¼ 0.007) (Table 3), with no evidence of treatment
effects (active vs. placebo) with shorter ischemic
times (interaction p value ¼ 0.027). The interaction
with ischemic time was not statistically significant
when treatment was assessed as a 3-level categorical
variable (Table 3) or as a trend across treatment
TABLE 1 Baseline Clinical Characteristics, Ischemic Time of the Randomized Participants (n ¼ 440)
<2 h (n ¼ 151) $2 But <4 h (n ¼ 144) $4 to 6 h (n ¼ 145) p Value
Clinical
Age, yrs 58.8  8.8 61.8  10.8 59.5  10.6 0.027*
Male 97 (90.7) 195 (83.0) 82 (83.7) 0.160†
Race, white 97 (90.7) 219 (93.2) 97 (99.0) 0.023†
Body mass index, kg/m2 28.4  5.3 28.5  4.8 27.8  4.4 0.704*
Presenting characteristics
Heart rate, beats/min 72.8  25.0 71.6  15.9 76.1  17.6 0.136*
Systolic blood pressure, mm Hg 128  24 134  26 138  25 0.026*
Diastolic blood pressure, mm Hg 79  15 80  16 83  16 0.146*
Infarct location
Anterior 54 (50.5) 103 (43.8) 34 (34.7) 0.073†
Inferior 46 (43.0) 107 (45.5) 54 (55.1) 0.181†
Lateral 3 (2.8) 0 (0.0) 0 (0.0) 0.025†
Posterior 4 (3.7) 21 (8.9) 8 (8.2) 0.223†
Other 0 (0.0) 4 (1.7) 2 (2.0) 0.422†
Medical history
Hypertension‡ 29 (27.1) 81 (34.5) 31 (31.6) 0.417†
Diabetes mellitus‡ 11 (10.3) 34 (14.5) 11 (11.2) 0.565†
Hypercholesterolemia‡ 22 (20.6) 59 (25.1) 21 (21.4) 0.615†
Smoking‡
Current 52 (48.6) 106 (45.1) 51 (52.0) 0.490†
Former, stopped >3 months 14 (13.1) 51 (21.7) 19 (19.4) 0.168†
Never 41 (38.3) 78 (33.2) 28 (28.6) 0.344†
Percutaneous coronary intervention 4 (3.7) 9 (3.8) 7 (7.1) 0.401†
Coronary artery bypass graft surgery 0 (0.0) 0 (0.0) 0 (0.0) –
Angina 0 (0.0) 13 (5.5) 4 (4.1) 0.024†
Myocardial infarction 3 (2.8) 12 (5.1) 5 (5.1) 0.652†
Stroke or transient ischemic attack‡ 2 (1.9) 2 (0.9) 1 (1.0) 0.833†
Peripheral vascular disease‡ 1 (0.9) 8 (3.4) 3 (3.1) 0.459†
Pre-existing maintenance medication
Aspirin 14 (13.1) 37 (15.7) 15 (15.3) 0.848†
P2Y12 inhibitor
Clopidogrel 1 (0.9) 0 (0.0) 1 (1.0) 0.217†
Ticagrelor or prasugrel 6 (5.6) 11 (4.7) 3 (3.1) 0.750†
Glycoprotein IIb/IIIa inhibitor 27 (25.7) 30 (12.9) 16 (17.6) 0.017†
Statin 23 (21.5) 52 (22.1) 22 (22.4) 1.0†
Beta-blocker 6 (5.6) 20 (8.5) 16 (16.3) 0.030†
ACE inhibitor or ARB 15 (14.0) 46 (19.6) 17 (17.3) 0.457†
Mineralocorticoid receptor antagonist 3 (2.8) 1 (0.4) 0 (0.0) 0.10†
Symptom onset to arrival at PPCI center, h:min 1:16 (0:59–1:26) 2:12 (1:53–2:44) 4:20 (3:51–4:58) <0.001§
Arrival at PPCI center to reperfusion, min 22 (17–32) 25 (20–36) 26 (19–38) 0.054§
Symptom onset to reperfusion, h:min 1:42 (1:28–1:52) 2:44 (2:22–3:15) 4:47 (4:21–5:31) <0.001§
Initial blood results on admission
Hemoglobin, g/l 145.8  12.1 145.1  14.2 146.0  12.3 0.795*
Platelet count, 109 l 260  55 259  61 265  73 0.777*
Creatinine, mmol/l 83.8  17.5 82.0  20.4 75.6  16.0 0.012*
Troponin, ng/l 37 (18–69) 57 (29–102) 129 (66–246) <0.001§
Values are mean  SD, n (%), or median (interquartile range). *The p value was derived using analysis of variance. †The p value was derived using Fisher exact test. ‡At least 1
risk factor for coronary artery disease was required for eligibility. Diabetes mellitus was defined as a history of diet-controlled or treated diabetes. §The p value was derived
using Kruskal-Wallis test.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; IQR ¼ interquartile range; PPCI ¼ primary percutaneous coronary intervention.
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mates demonstrated a similar pattern. No significant
interactions were observed between ischemic time
and treatment for left ventricular end-systolic or end-diastolic volumes, regardless of how the treatment
effect was modelled. Patterns of treatment effects in
relation to left ventricular measures at 3 months
were similar, though with fewer statistically
TABLE 2 Pre-Specified Analyses of the Primary and Secondary Outcomes, Adjusting for Location of MI, by Subgroups of Ischemic Time
Randomized Treatment Group Treatment Effect (Trend per 10-mg Dose Increase)
n (Missing) Placebo (n ¼ 151) Alteplase 10 mg (n ¼ 144) Alteplase 20 mg (n ¼ 145) Estimate (95% CI), p Value Interaction p Value
Primary Outcome: Extent of MVO (% of LV Mass) at 2–7 Days
Summaries of data on original scale (% of LV mass).
Overall 396 (44) 2.32  4.31 2.61  4.49 3.48  5.83
Ischemic time
<2 h 98 (9) 1.35  2.67 1.49  2.71 2.73  5.03
$2 but <4 h 215 (20) 3.01  4.99 3.11  5.28 3.16  5.69
$4 to 6 h 83 (15) 1.14  2.62 3.11  4.58 5.20  6.86
Summaries of data on square root–transformed scale, with treatment effect estimates (change in OMVO per 10-mg increase in alteplase dose); estimates reported for all
patients, and by subgroups of ischemic time, with interaction test p value.
Overall 396 (44) 0.91  1.22 0.99  1.28 1.15  1.48 0.12 (0.04 to 0.28), 0.128
Ischemic time 0.018
<2 h 98 (9) 0.63  0.99 0.71  1.01 0.93  1.39 0.12 (0.21 to 0.46), 0.470
$2 but <4 h 215 (20) 1.12  1.33 1.10  1.39 1.06  1.44 0.03 (0.23 to 0.18), 0.791
$4 to 6 h 83 (15) 0.54  0.94 1.14  1.37 1.64  1.61 0.56 (0.21 to 0.91), 0.009
Secondary Outcomes
MVO present at 2–7 days. Treatment effect reported as odds ratio per 10-mg increase in alteplase dose.
Overall 396 (44) 59 (43.4) 58 (45.0) 59 (45.0) 1.04 (0.82 to 1.33), 0.733
Ischemic time 0.076
<2 h 98 (9) 9 (33.3) 16 (40.0) 11 (35.5) 1.01 (0.59 to 1.73), 0.966
$2 but <4 h 215 (20) 42 (50.6) 28 (47.5) 32 (43.8) 0.88 (0.64 to 1.20), 0.411
$4 to 6 h 85 (15) 8 (30.8) 14 (46.7) 16 (59.3) 1.84 (1.04 to 3.24), 0.036
Myocardial hemorrhage (% of LV mass) at 2–7 days. Treatment effect reported as mean change per 10-mg increase in alteplase dose.
Overall 360 (80) 1.56  3.78 1.98  3.68 2.45  4.80 0.46 (0.005 to 0.97), 0.075
Ischemic time 0.038
<2 h 90 (17) 0.26  0.71 1.21  2.60 1.37  2.48 0.42 (0.67 to 1.52), 0.449
$2 but <4 h 196 (39) 2.32  4.62 2.34  4.10 2.38  4.92 0.04 (0.62 to 0.70), 0.903
$4 to 6 h 74 (24) 0.48  1.27 2.39  4.08 3.95  6.19 1.74 (0.61 to 2.87), 0.003
Myocardial hemorrhage present at 2–7 days. Treatment effect reported as odds ratio per 10-mg increase in alteplase dose.
Overall 378 (62) 52 (40.6) 54 (44.6) 56 (43.4) 1.07 (0.83 to 1.37), 0.603
Ischemic time 0.044
<2 h 96 (11) 7 (26.9) 15 (38.5) 11 (35.5) 1.16 (0.67 to 2.02), 0.597
$2 but <4 h 202 (33) 38 (49.4) 25 (46.3) 29 (40.8) 0.85 (0.61 to 1.18), 0.324
$4 to 6 h 80 (18) 7 (28.0) 14 (50.0) 16 (59.3) 1.93 (1.09 to3.45), 0.025
Infarct size (% of LV mass) at 2–7 days. Data analyzed on original scale; treatment effect reported as relative increase per 10-mg increase in alteplase dose.
Overall 396 (44) 26.3  13.7 27.3  12.4 26.7  13.4 0.19 (1.23 to 1.62), 0.7921
Ischemic time 0.527
<2 h 98 (9) 22.9  15.4 25.9  13.5 24.3  15.0 0.18 (3.25 to 2.89), 0.908
$2 but <4 h 215 (20) 28.0  13.9 27.3  11.9 27.3  13.5 0.23 (2.10 to 1.63), 0.807
$4 to 6 h 83 (15) 24.5  10.6 29.1  12.1 27.6  11.5 1.85 (1.36 to 5.05), 0.258
LV ejection fraction at 2–7 days. Treatment effect reported as mean change per 10-mg increase in alteplase dose.
Overall 400 (40) 44.5  8.8 43.6  8.1 44.2  8.4 0.2 (1.1 to 0.8), 0.748
Ischemic time 0.105
<2 h 99 (8) 45.2  8.3 45.1  7.3 45.2  7.1 0.4 (1.6 to 2.5), 0.664
$2 but <4 h 216 (19) 43.4  9.5 44.2  8.0 44.2  8.8 0.3 (0.9 to 1.5), 0.617
$4 to 6 h 85 (13) 47.0  6.2 40.7  8.8 42.9  8.7 2.2 (4.3 to 0.1), 0.041
LV end-systolic volume at 2–7 days. Data analyzed on a logarithmic scale; treatment effect reported as relative increase per 10-mg increase in alteplase dose.
Overall 400 (40) 95.8  29.8 104.1  33.0 96.6  30.8 1.00 (0.97 to 1.04), 0.897
Ischemic time 0.277
<2 h 99 (8) 87.3  23.7 102.0  29.2 96.1  30.4 1.03 (0.95 to 1.11), 0.470
$2 but <4 h 216 (19) 100.5  32.4 101.2  34.8 95.9  31.1 0.98 (0.93 to 1.02), 0.359
$4 to 6 h 85 (13) 90.2  24.2 112.1  33.6 99.2  31.3 1.05 (0.97 to 1.13), 0.269
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TABLE 2 Continued
Randomized Treatment Group Treatment Effect (Trend per 10-mg Dose Increase)
n (Missing) Placebo (n ¼ 151) Alteplase 10 mg (n ¼ 144) Alteplase 20 mg (n ¼ 145) Estimate (95% CI), p Value Interaction p Value
Secondary Outcomes
LV end-diastolic volume at 2–7 days. Data analyzed on a logarithmic scale; treatment effect reported as relative increase per 10-mg increase in alteplase dose.
Overall 400 (40) 171.1  36.5 182.5  40.8 171.4  40.1 1.00 (0.97 to 1.03), 0.960
Ischemic time 0.332
<2 h 99 (8) 160.1  38.8 183.8  36.2 173.7  43.4 1.03 (0.98 to 1.10), 0.245
$2 but <4 h 216 (19) 175.5  35.6 178.9  43.0 170.3  39.3 0.98 (0.95 to 1.02), 0.366
$4 to 6 h 85 (13) 169.0  35.7 187.4  42.6 171.8  39.5 1.01 (0.95 to 1.07), 0.831
Myocardial salvage (% LV) at 2–7 days. Data analyzed on original scale; treatment effect reported as relative increase per 10-mg increase in alteplase dose.
Overall 396 (44) 14.12  9.17 14.60  9.78 14.35  10.17 0.04 (1.10 to 1.17), 0.948
Ischemic time 0.125
<2 h 98 (9) 17.84  11.16 15.32  8.48 20.16  11.11 1.09 (1.35 to 3.52), 0.382
$2 but <4 h 215 (20) 12.75  8.16 14.71  10.13 13.51  9.14 0.43 (1.05 to 1.92), 0.566
$4 to 6 h 83 (15) 14.62  9.22 13.41  10.88 9.96  9.00 2.27 (4.81 to 0.27), 0.080
Area under the troponin T (mg/l) curve, 0–24 h. Data analyzed on a logarithmic scale; treatment effect reported as ratios per 10-mg increase in alteplase dose.
Overall 317 (123) 4.54  5.58 5.94  7.53 5.84  6.23 1.25 (1.07 to 1.46), 0.006
Ischemic time 0.191
<2 h 85 (22) 3.40  5.62 3.63  3.96 5.27  5.53 1.41 (1.02 to 1.95), 0.036
$2 but <4 h 163 (72) 5.42  5.96 6.23  7.07 5.59  5.50 1.10 (0.90 to 1.36), 0.353
$4 to 6 h 69 (29) 3.09  3.44 8.43  10.46 7.17  8.53 1.54 (1.08 to 2.20), 0.016
Values are mean  SD or n (%), unless otherwise indicated. All outcomes were pre-specified. Treatment effect estimates derived from linear or logistic regression models, modelling the treatment effect as a
linear trend across alteplase dose groups (0 mg vs. 10 mg vs. 20 mg). Interaction test p values reported from regression models with ischemic time included as a 3-level categorical variable and interaction
with treatment effect. Treatment effect estimates and tests of interaction are based on models assuming a linear trend with alteplase dose. The p values and 95% CI have not been adjusted for multiplicity,
therefore these analyses should be interpreted as exploratory and not definitive.
CI ¼ confidence interval; LV ¼ left ventricular; MI ¼ myocardial infarction; MVO ¼ microvascular obstruction.
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There was no evidence of any treatment effects in
relation to infarct size, or myocardial salvage index
at 2 to 7 days or 3 months.
BLOOD CHEMISTRY. The AUC for troponin T (ng/l)
measured at baseline and 2 and 24 h post-reperfusion
in 317 subjects was increased in both treatment
groups compared with the placebo group, for those
treated with alteplase, the relative difference was 1.53
(95% CI: 1.12 to 2.11; p ¼ 0.008) (16). Troponin T AUC
was 35% higher in patients treated with 20 mg of
alteplase versus placebo. There was no interaction
among troponin T AUC, ischemic time, and treatment
with alteplase compared with placebo (Table 2).
HEMATOLOGY AND COAGULATION, 2-H TIME POINT. By
2 h after study drug administration, circulating
concentrations of fibrin D-dimers were increased in
the alteplase groups compared with in the placebo
group (Supplemental Table 3). There were no sta-
tistically significant interactions observed for fibrin
D-dimers, prothrombin F1 þ 2 (a measure of
thrombin activation), tissue plasminogen activator
(a measure of endogenous tissue plasminogen
activator and any circulating alteplase), plasmin-
ogen, or fibrinogen (Supplemental Table 4).DISCUSSION
The principal findings from the T-TIME trial were that
the intervention was feasible but not effective (16).
Adjunctive, low-dose intracoronary alteplase admin-
istered after coronary reperfusion and before stent
implantation did not reduce the amount of MVO
revealed by cardiac CMR 2 to 7 days post-STEMI.
In this pre-specified analysis, low-dose intra-
coronary alteplase administered during PPCI was
associated with an increase in the amount of MVO in
patients with an ischemic time of 4 h or more. When
the interaction test between ischemic time and
treatment was performed as a trend across treatment
groups, we observed a statistically significant inter-
action, indicating a dose-dependent increase in MVO
with alteplase in association with the duration of
ischemia. An increase in the proportion of patients
with myocardial hemorrhage as well as an increase in
the amount of hemorrhage by ischemic time and
treatment with alteplase (10 mg, 20 mg) was
observed. These dose effects were driven by those
patients receiving 20 mg of alteplase. In the subgroup
of patients with the longest ischemic time ($4 to 6 h),
treatment with 20 mg alteplase was also associated
with a lower left ventricular ejection fraction at 2 to
FIGURE 2 Clinical Case Examples
Two patients, both with acute lateral ST-segment elevation myocardial infarction treated successfully with primary percutaneous coronary intervention. Each patient
had TIMI (Thrombolysis In Myocardial Infarction) flow grade 0 at initial angiography and TIMI flow grade 3 (normal flow grade) at the end of percutaneous coronary
intervention. The first with an ischemic time of 5 h and the second 3 h. Cardiac magnetic resonance (CMR) was performed at 3 days post-reperfusion. (A) Patient with
hemorrhagic infarction on CMR. Diagnostic coronary angiogram demonstrated an occluded circumflex artery (yellow arrow). T2*-CMR (far right) revealed myocardial
hemorrhage (white arrow) within the infarct core. Late gadolinium-enhanced CMR revealed microvascular obstruction (middle, red arrow) within the bright area of
infarction. The microvascular obstruction within the infarct core spatially corresponded with the myocardial hemorrhage. This represents a case of failed microvascular
reperfusion despite successful percutaneous coronary intervention. (B) Patient with a lateral infarct but no CMR evidence of reperfusion injury. Diagnostic coronary
angiogram demonstrated an occluded circumflex artery (yellow arrow). Late gadolinium-enhanced CMR revealed a lateral infarct with no evidence of microvascular
obstruction and no evidence of hemorrhagic transformation on T2*-CMR. This represents a case of successful microvascular reperfusion.
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approach, especially in those STEMI patients pre-
senting with an ischemic time of 4 h or more, in
whom MVO and myocardial hemorrhage may
be increased. Clinical case examples are shown in
Figure 2. Whether giving low-dose fibrinolysis at the
end of PPCI in patients presenting with an ischemic
time <4 h might be beneficial merits prospective
assessment.
The mechanism for an increase in microvascular
injury in patients with an ischemic time $4 to 6 h
treated with alteplase likely involves hemorrhagic
transformation within the infarct core. Prolonged
ischemia leads to capillary degradation (26) and
myocyte necrosis, and in these circumstances, alte-
plase appears to promote tissue hemorrhage.
Myocardial hemorrhage underpins adverse left ven-
tricular remodeling (27,28) and is independently
predictive of an adverse cardiac prognosis in the
longer term (27,29). An increase in the extravasationof blood into the interstitial space at the infarct core
results in the external compression of the capillary
bed with an associated exponential increase in
microvascular resistance. This external compressive
mass potentiates progression of microvascular dam-
age. Myocardial hemorrhage is a pathological subset
of MVO, as revealed by CMR imaging (27), in addition
to the effect on microvascular injury, the increase in
interstitial mass increases the extent of MVO as
measured by CMR due to the associated mass effect.
We observed a close relationship between MVO
and myocardial hemorrhage. Myocardial hemorrhage
did not occur in the absence of MVO, although hem-
orrhage was present in the majority of patients with
MVO, it was not universal. We found that myocardial
hemorrhage occurred in all patients with MVO who
presented with a prolonged ischemic time (4 h or
more) who then went on to receive alteplase (10-mg
or 20-mg dose). This was not the case in those pa-
tients receiving placebo or in patients with an
CENTRAL ILLUSTRATION Efficacy of Intracoronary Alteplase and Mechanism of Increased Microvascular Injury in
Patients With an Ischemic Time of $4 to 6 h
FINDINGS
Analysis in patients with ischemic time ≥4 h
0.56% per 10 mg (95% CI: 0.21-0.91)
p = 0.009
1.74% per 10 mg (95% CI: 0.61-2.87)
p = 0.003
EXTENT OF MICROVASCULAR OBSTRUCTION
Placebo
1.1% 3.1% 5.2%
10 mg Alteplase 20 mg Alteplase
EXTENT OF MYOCARDIAL HEMORRHAGE
4.0%
20 mg Alteplase
2.4%
10 mg AlteplasePlacebo
0.5%
QUESTION
Does the efficacy of adjunctive intracoronary alteplase associate with ischemic time?
POPULATION
440 patients
≥2 to <4 h
n = 235
<2 h
n = 107
≥4 to 6 h
n = 98
Placebo
n = 29 n = 38 n = 31
10 mg Alteplase 20 mg Alteplase
McCartney, P.J. et al. J Am Coll Cardiol. 2020;75(12):1406–21.
The flow diagram groups participants by ischemic time into 3 categories ($4 to 6 h, n ¼ 98;$2 but <4 h, n ¼ 235; <2 h, n ¼ 107), those with an ischemic time of 4 h or
more are subgrouped according to treatment group allocation (placebo, n ¼ 29; 10 mg alteplase n¼ 38; 20 mg alteplase, n¼ 31). The effect of intracoronary alteplase
on the extent of microvascular obstruction and myocardial hemorrhage is shown, including the effect estimates. The estimated mean difference on a square root scale
is shown for the extent of microvascular obstruction and the estimated mean difference for myocardial hemorrhage. There was a statistically significant increase in
microvascular obstruction and myocardial hemorrhage extent in those patients receiving alteplase. CI ¼ confidence interval.
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of patients with myocardial hemorrhage versus MVO
without myocardial hemorrhage by ischemic time and
treatment group highlights the potential deleterious
effects of adjunctive alteplase in patients with
established microvascular injury. The increase in the
extent of myocardial hemorrhage may be explained
by the observation that MVO and myocardial hemor-
rhage are the same phenomenon in the majority ofcases. A multicenter cohort study (30) previously re-
ported increases in myocardial hemorrhage in pa-
tients receiving periprocedural glycoprotein IIb/IIIa
inhibitor and an animal study (31) demonstrated an
increased incidence of myocardial hemorrhage with
the use of additional glycoprotein IIb/IIIa inhibitors.
More aggressive antithrombotic treatment may pro-
mote tissue hemorrhage especially in the context of
established microvascular injury.
TABLE 3 Pre-Specified Analyses of the Primary and Secondary Outcomes, Adjusting for Location of MI, by Subgroups of Ischemic Time and Interactions With
Treatment Group, Effect Estimates, and Interactions
Treatment Effect (Alteplase 20 mg vs. Alteplase 10 mg vs. Placebo) Treatment Effect (Alteplase vs. Placebo)
10 mg vs. Placebo Estimate (95% CI),
p Value
20 mg vs. Placebo Estimate (95% CI),
p Value
Interaction
p Value
Estimate (95% CI),
p Value
Interaction
p Value
Primary Outcome
Extent of MVO (% of LV mass) at 2–7 days. Treatment effects reported as mean differences in square root–transformed MVO between treatment groups (each dose vs. placebo
separately, and both active treatment groups combined vs. placebo).
Overall 0.11 (0.21 to 0.43), 0.511 0.24 (0.07 to 0.56), 0.128 0.18 (0.10 to 0.45), 0.204
Ischemic time 0.090 0.061
<2 h 0.09 (0.55 to 0.73), 0.783 0.25 (0.43 to 0.92), 0.476 0.16 (0.42 to 0.74), 0.592
$2 but <4 h 0.01 (0.45 to 0.42), 0.947 0.06 (0.47 to 0.35), 0.790 0.04 (0.40 to 0.32), 0.837
$4 to 6 h 0.53 (0.15 to 1.22), 0.128 1.12 (0.42 to 1.82), 0.002 0.81 (0.21 to 1.42), 0.009
Secondary Outcomes
MVO present at 2–7 days. Treatment effects reported as odds ratios between groups.
Overall 0.12 (0.68 to 1.84), 0.651 1.09 (0.67 to 1.77), 0.734 1.10 (0.72 to 1.69), 0.647
Ischemic time 0.240 0.147
<2 h 1.35 (0.49 to 3.78), 0.561 1.04 (0.35 to 3.11), 0.940 1.21 (0.47 to 3.09), 0.689
$2 but <4 h 0.89 (0.45 to 1.74), 0.726 0.77 (0.41 to 1.45), 0.410 0.82 (0.47 to 1.42), 0.476
$4 to 6 h 1.86 (0.61 to 5.61), 0.272 3.38 (1.08 to 10.55), 0.036 2.46 (0.92 to 6.60), 0.073
Myocardial hemorrhage (% of LV mass) at 2–7 days. Treatment effects reported as mean differences between groups.
Overall 0.55 (0.50 to 1.60), 0.304 0.93 (0.09 to 1.94), 0.074 0.75 (0.14 to 1.65), 0.100
Ischemic time 0.149 0.097
<2 h 0.94 (1.16 to 3.05), 0.380 0.90 (1.31 to 3.10), 0.425 0.93 (0.99 to 2.85), 0.343
$2 but <4 h 0.00 (1.43 to 1.44), 0.996 0.08 (1.24 to 1.41), 0.903 0.05 (1.12 to 1.22), 0.935
$4 to 6 h 1.63 (0.64 to 3.91), 0.160 3.49 (1.22 to 5.75), 0.003 2.57 (0.59 to 4.54), 0.011
Myocardial hemorrhage present at 2–7 days. Treatment effects reported as odds ratios between groups.
Overall 1.25 (0.75 to 2.08), 0.401 1.14 (0.69 to 1.89), 0.598 1.19 (0.77 to 1.85), 0.434
Ischemic time 0.150 0.059
<2 h 1.72 (0.58 to 5.09), 0.327 1.41 (0.45 to 4.43), 0.554 1.58 (0.58 to 4.28), 0.369
$2 but <4 h 0.89 (0.44 to 1.80), 0.748 0.72 (0.37 to 1.38), 0.322 0.79 (0.45 to 1.40), 0.418
$4 to 6 h 2.42 (0.76 to 7.64), 0.133 3.81 (1.19 to 12.25), 0.025 3.02 (1.08 to 8.42), 0.035
Infarct size (% of LV mass) at 2–7 days. Data analyzed on original scale; treatment effect reported as relative increase per 10-mg increase in alteplase dose.
Overall 1.23 (1.66 to 4.11), 0.404 0.38 (2.48 to 3.23), 0.795 0.79 (1.68 to 3.27), 0.530
Ischemic time 0.600 0.475
<2 h 3.36 (2.45 to 9.16), 0.258 0.17 (6.32 to 5.97), 0.956 1.82 (3.44 to 7.08), 0.498
$2 but <4 h 0.47 (4.44 to 3.50), 0.818 0.46 (4.20 to 3.28), 0.810 0.46 (3.73 to 2.80), 0.780
$4 to 6 h 2.85 (3.41 to 9.11), 0.373 3.71 (2.70 to 10.12), 0.257 3.26 (2.25 to 8.77), 0.246
LV ejection fraction at 2–7 days. Treatment effects reported as mean differences between groups.
Overall 0.9 (2.8 to 1.0), 0.367 0.3 (2.2 to 1.6), 0.752 0.6 (2.2 to 1.1), 0.483
Ischemic time 0.117 0.027
<2 h 0.2 (4.0 to 3.6), 0.915 0.9 (3.2 to 4.9), 0.679 0.3 (3.2 to 3.7), 0.884
$2 but <4 h 0.7 (2.0 to 3.3), 0.616 0.6 (1.8 to 3.1), 0.621 0.6 (1.5 to 2.8), 0.557
$4 to 6 h 5.5 (9.5 to 1.4), 0.008 4.5 (8.7 to 0.2), 0.039 5.0 (8.6 to 1.4), 0.007
LV end-systolic volume at 2–7 days. Data analyzed on a logarithmic scale; treatment effects reported as relative differences between groups.
Overall 1.08 (1.01 to 1.16), 0.027 1.00 (0.94 to 1.08), 0.907 1.04 (0.98 to 1.11), 0.184
Ischemic time 0.222 0.053
<2 h 1.17 (1.01 to 1.34), 0.032 1.06 (0.92 to 1.23), 0.424 1.12 (0.99 to 1.27), 0.082
$2 but <4 h 1.00 (0.91 to 1.11), 0.943 0.96 (0.87 to 1.05), 0.346 0.98 (0.90 to 1.06), 0.576
$4 to 6 h 1.21 (1.04 to 1.40), 0.016 1.10 (0.94 to 1.28), 0.255 1.15 (1.01 to 1.32), 0.038
LV end-diastolic volume at 2–7 days. Data analyzed on a logarithmic scale; treatment effects reported as relative differences between groups.
Overall 1.06 (1.01 to 1.12), 0.947 1.00 (0.95 to 1.05), 0.947 1.03 (0.98 to 1.08), 0.210
Ischemic time 0.314 0.081
<2 h 1.16 (1.04 to 1.29), 0.007 1.08 (0.96 to 1.21), 0.211 1.12 (1.02 to 1.24), 0.021
$2 but <4 h 1.01 (0.94 to 1.09), 0.743 0.97 (0.90 to 1.04), 0.349 0.99 (0.93 to 1.05), 0.676
$4 to 6 h 1.10 (0.98 to 1.23), 0.117 1.01 (0.90 to 1.14), 0.814 1.06 (0.95 to 1.17), 0.282
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TABLE 3 Continued
Treatment Effect (Alteplase 20 mg vs. Alteplase 10 mg vs. Placebo) Treatment Effect (Alteplase vs. Placebo)
10 mg vs. Placebo Estimate (95% CI),
p Value
20 mg vs. Placebo Estimate (95% CI),
p Value
Interaction
p Value
Estimate (95% CI),
p Value
Interaction
p Value
Secondary Outcomes
Myocardial salvage (% LV) at 2–7 days. Data analyzed on original scale; treatment effect reported as relative increase per 10-mg increase in alteplase dose.
Overall 0.04 (2.26 to 2.34), 0.975 0.08 (2.20 to 2.35), 0.948 0.06 (1.92 to 2.03), 0.955
Ischemic time 0.071 0.337
<2 h 2.44 (7.03 to 2.16), 0.299 1.99 (2.87 to 6.86), 0.422 0.51 (4.70 to 3.68), 0.811
$2 but <4 h 2.00 (1.14 to 5.14), 0.212 0.81 (2.15 to 3.77), 0.592 1.35 (1.25 to 3.94), 0.309
$4 to 6 h 1.60 (6.55 to 3.35), 0.527 4.54 (9.61 to 0.53), 0.080 3.00 (7.39 to 1.38), 0.179
Area under the troponin T (mg/l) curve, 0–24 h. Data analyzed on a logarithmic scale; treatment effects reported as relative differences between groups.
Overall 1.61 (1.17 to 2.22), 0.003 1.56 (1.14 to 2.13), 0.006 1.58 (1.21 to 2.08), 0.001
Ischemic time 0.257 0.081
<2 h 1.76 (0.96 to 3.21), 0.067 2.00 (1.05 to 3.79), 0.034 1.86 (1.08 to 3.19), 0.025
$2 but <4 h 1.24 (0.78 to 1.96), 0.362 1.21 (0.80 to 1.83), 0.363 1.22 (0.85 to 1.76), 0.278
$4 to 6 h 2.82 (1.44 to 5.54), 0.003 2.44 (1.20 to 4.94), 0.014 2.64 (1.44 to 4.83), 0.002
All outcomes were pre-specified. Treatment effect estimates derived from linear or logistic regression models, modelling the treatment effect as a 3-level categorical variable or as a 2-level categorical
variable (active vs. placebo). Interaction test p values reported from regression models with ischemic time included as a 3-level categorical variable and interaction with treatment effect. P values and 95% CI
presented in this table have not been adjusted for multiplicity, therefore these analyses should be interpreted as exploratory and not definitive.
Abbreviations as in Table 2.
J A C C V O L . 7 5 , N O . 1 2 , 2 0 2 0 McCartney et al.
M A R C H 3 1 , 2 0 2 0 : 1 4 0 6 – 2 1 Low-Dose Alteplase During PPCI According to Ischemic Time
1417The relationship between vascular permeability
post-MI and tissue hemorrhage was highlighted in a
study investigating the role of angiopoietin-like pro-
tein 2, which has been linked to endothelial cell
junction stability and vascular permeability in mice.
The investigators demonstrated that angiopoietin-like
protein 2 mediates protection against post-ischemic
tissue damage through preservation of the endothe-
lial cell tissue barrier with associated reductions
in myocardial hemorrhage and infarct size (26).
The detection of myocardial hemorrhage in vivo is
limited by difficulty in obtaining reliable diagnostic
quality images in a proportion of patients, which for
T2* imaging typically requires long breath holds with
minimal respiratory movement. This is highlighted by
the observation that in our study, an assessment of
the extent of MVO was possible in 396 of 440 partic-
ipants compared with 360 of 440 for myocardial
hemorrhage. This difference, reflecting a limitation in
the diagnostic performance of T2* imaging, is com-
parable to previous reports (32). These results help
explain why detection of myocardial hemorrhage may
prove challenging, especially in those patients with a
limited amount of myocardial hemorrhage. The result
provides insights into why some patients may have
detectable MVO but no myocardial hemorrhage.
The overall clinical relevance of our findings is
highlighted by a trend on ischemic time toward
reduced ejection fraction in patients receiving alte-
plase versus placebo. We provide evidence that
increased myocardial hemorrhage is causally related
to a reduction in left ventricular function and adverse
left ventricular remodeling.The T-TIME study has several strengths. The pri-
mary and secondary outcomes were analyzed using
core laboratory methods. The study intervention
and source data analyses were conducted in a
double-blind manner, minimizing the risk of bias. The
design specified multimodality testing including a
time-course AUC analysis of the circulating concen-
trations of troponin T. The coagulation results have
been useful to inform the safety of intracoronary
alteplase as an adjunct during PPCI.
MVO presents an unmet therapeutic need and there
is widespread interest in the potential efficacy of intra-
coronary fibrinolytic therapy during PPCI. Two multi-
center, international trials are scheduled to investi-
gate the efficacy of reduced doses of either alteplase
(STRIVE [Adjunctive, Low-dose tPA in Primary PCI for
STEMI]; NCT03335839) or tenecteplase (RESTORE-MI
[Restoring Microcirculatory Perfusion in ST-Elevation
Myocardial Infarction (STEMI)]; ACTRN12618
000778280) (Supplemental Appendix). Considering
eligibility criteria in these trials, the ischemic time
limit is 12 h. Furthermore, RESTORE-MI selects pa-
tients with evidence of microvascular dysfunction
(index of microcirculatory resistance >32) in the
infarct-related artery at the end of PCI. Our results
suggest this risk-based selection strategy may enroll
patients at risk of myocardial hemorrhage that, based
on our findings, may be exacerbated by intracoronary
lytic therapy. The new knowledge from the T-TIME
study seems relevant to the design of these trials and
to clinicians in practice when considering the use of
intracoronary alteplase as a bail-out option in patients
with massive thrombosis. Finally, PPCI is not available
TABLE 4 Pre-Specified Analyses of the Primary and Selected Secondary Outcomes, Adjusting for Location of MI, by Subgroups of Ischemic Time and MI Location
(Anterior/Nonanterior)
Randomized Treatment Group Treatment Effect (Trend per 10-mg Dose Increase)
n (Missing) Placebo (n ¼ 151) Alteplase 10 mg (n ¼ 144) Alteplase 20 mg (n ¼ 145) Estimate (95% CI), p Value Interaction p Value
Primary Outcome
Extent of MVO (% of LV mass) at 2–7 days. Summaries of data on square root–transformed scale, with treatment effect estimates (change in OMVO per 10-mg increase in
alteplase dose); estimates reported for all patients, and by subgroups of ischemic time, with interaction test p value.
Anterior MI
Overall 178 (15) 1.16  1.44 1.08  1.28 1.42  1.64 0.15 (0.11 to 0.42), 0.249
Ischemic time 0.264
<2 h 50 (4) 0.81  1.16 0.77  0.98 1.16  1.51 0.19 (0.32 to 0.70), 0.458
$2 but <4 h 96 (9) 1.37  1.55 1.28  1.40 1.41  1.61 0.02 (0.33 to 0.36), 0.929
$4 to 6 h 32 (2) 0.77  1.26 1.11  1.37 2.10  2.06 0.65 (0.04 to 1.34), 0.064
Nonanterior MI
Overall 218 (29) 0.72  0.99 0.91  1.29 0.92  1.29 0.10 (0.09 to 0.29), 0.316
Ischemic time 0.049
<2 h 48 (5) 0.47  0.81 0.66  1.04 0.56  1.12 0.05 (0.40 to 0.51), 0.823
$2 but <4 h 119 (11) 0.91  1.09 0.96  1.39 0.78  1.24 -0.06 (0.31 to 0.19), 0.630
$4 to 6 h 51 (13) 0.42  0.74 1.16  1.42 1.45  1.41 0.51 (0.13 to 0.90), 0.009
Secondary Outcomes
MVO present at 2–7 days. Treatment effect reported as odds ratio per 10-mg increase in alteplase dose.
Anterior MI
Overall 178 (15) 28 (46.7) 29 (49.2) 31 (52.5) 1.16 (0.80 to 1.66), 0.437
Ischemic time 0.613
<2 h 50 (4) 5  38.5 8  44.4 8  42.1 1.07 (0.52 to 2.17), 0.862
$2 but <4 h 96 (9) 20  52.6 14  53.8 18  56.2 1.08 (0.67 to 1.72), 0.764
$4 to 6 h 32 (2) 3  33.3 7  46.7 5  62.5 1.82 (0.67 to 4.94), 0.237
Nonanterior MI
Overall 218 (29) 31 (40.8) 29 (41.4) 28 (38.9) 0.96 (0.69 to 1.33), 0.788
Ischemic time 0.089
<2 h 48 (5) 4  28.6 8  36.4 3  25.0 0.93 (0.41 to 2.15), 0.874
$2 but <4 h 119 (11) 22  48.9 14  42.4 14  34.1 0.74 (0.48 to 1.14), 0.169
$4 to 6 h 51 (13) 5  29.4 7  46.7 11  57.9 1.81 (0.91 to 3.59), 0.092
Myocardial hemorrhage (% of LV mass) at 2–7 days. Treatment effect reported as mean change per 10-mg increase in alteplase dose.
Anterior MI
Overall 148 (35) 2.29  5.13 2.22  3.54 3.41  5.81 0.69 (0.25 to 1.63), 0.148
Ischemic time 0.079
<2 h 44 (10) 0.38  0.85 1.43  2.94 1.86  2.72 0.71 (1.13 to 2.54), 0.450
$2 but <4 h 87 (18) 3.30  6.07 2.89  4.07 3.52  6.01 0.10 (1.09 to 1.29), 0.867
$4 to 6 h 27 (7) 0.26  0.50 1.94  3.14 6.89  9.33 3.32 (0.79 to 5.84), 0.010
Nonanterior MI
Overall 202 (45) 1.05  2.34 1.78  3.82 1.70  3.70 0.32 (0.23 to 0.86), 0.255
Ischemic time 0.250
<2 h 46 (7) 0.18  0.61 1.04  2.38 0.63  1.95 0.24 (1.06 to 1.53), 0.721
$2 but <4 h 109 (21) 1.52  2.84 1.87  4.14 1.52  3.76 0.00 (0.72 to 0.72), 1.000
$4 to 6 h 47 (17) 0.57  1.49 2.88  5.01 2.80  4.29 1.11 (0.01 to 2.20), 0.047
Myocardial hemorrhage present at 2–7 days. Treatment effect reported as odds ratio per 10-mg increase in alteplase dose.
Anterior MI
Overall 168 (25) 25 (44.6) 27 (49.1) 28 (49.1) 1.12 (0.77 to 1.62), 0.558
Ischemic time 0.661
<2 h 48 (6) 4  33.3 8  47.1 8  42.1 1.16 (0.56 to 2.41), 0.689
$2 but <4 h 90 (15) 18  50.0 12  50.0 15  50.0 1.00 (0.62 to 1.62), 1.000
$4 to 6 h 30 (4) 3  37.5 7  50.0 5  62.5 1.67 (0.61 to 4.59), 0.323
Nonanterior MI
Overall 210 (37) 27 (37.5) 27 (40.9) 28 (38.9) 1.02 (0.73 to 1.43), 0.910
Ischemic time 0.045
<2 h 48 (5) 3  21.4 7 (31.8) 3  25.0 1.11 (0.47 to 2.64), 0.811
$2 but <4 h 112 (18) 20  48.8 13 (43.3) 14  34.1 0.74 (0.47 to 1.15), 0.181
$4 to 6 h 50 (14) 4  23.5 7 (50.0) 14  34.1 2.06 (1.02 to 4.18), 0.044
Continued on the next page
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TABLE 4 Continued
Randomized Treatment Group Treatment Effect (Trend per 10-mg Dose Increase)
n (Missing) Placebo (n ¼ 151) Alteplase 10 mg (n ¼ 144) Alteplase 20 mg (n ¼ 145) Estimate (95% CI), p Value Interaction p Value
Secondary Outcomes
Infarct size (% of LV mass) at 2–7 days. Data analyzed on original scale; treatment effect reported as relative increase per 10-mg increase in alteplase dose.
Anterior MI
Overall 178 (15) 33.1  14.3 33.8  11.9 31.9  15.3 0.40 (2.90 to 2.10), 0.756
Ischemic time 0.453
<2 h 50 (8) 27.5  17.0 34.5  13.8 28.1  16.4 0.16 (5.01 to 4.70), 0.950
$2 but <4 h 96 (19) 36.1  13.6 32.6  12.1 33.4  14.7 1.41 (4.66 to 1.85), 0.3974
$4 to 6 h 32 (13) 28.7  10.3 35.1  9.5 35.1  14.9 3.30 (3.30 to 9.89), 0.327
Nonanterior MI
Overall 218 (29) 20.9  10.6 21.8  10.0 22.3  9.9 0.65 (0.97 to 2.27), 0.431
Ischemic time 0.874
<2 h 48 (5) 18.7  12.8 18.9  8.2 18.2  10.5 0.22 (4.11 to 3.67), 0.912
$2 but <4 h 119 (11) 21.1  10.1 23.2  10.1 22.6  10.3 0.73 (1.41 to 2.86), 0.505
$4 to 6 h 51 (13) 22.3  10.3 23.2  11.7 24.5  8.2 1.10 (2.20 to 4.40), 0.513
Values are mean  SD or n (%), unless otherwise indicated. All outcomes were pre-specified. Treatment effect estimates derived from linear or logistic regression models, modelling the treatment effect as a
linear trend across alteplase dose groups (0 mg vs. 10 mg vs. 20 mg). Interaction test p values reported from regression models with ischemic time included as a 3-level categorical variable and interaction
with treatment effect. Treatment effect estimates and tests of interaction are based on models assuming a linear trend with alteplase dose. The p values and 95% CI have not been adjusted for multiplicity,
therefore these analyses should be interpreted as exploratory and not definitive.
Abbreviations as in Table 2.
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1419for many patients due to both geographical and so-
cioeconomic factors (33). As a result, intravenous
thrombolysis is the primary reperfusion strategy for
many STEMI patients worldwide. Our findings are
potentially relevant for these patients. The GUSTO-1
(Global Utilization of t-Pa and Streptokinase for
Occluded Coronary Arteries) trial evaluated the effects
of intravenous thrombolysis in over 40,000 STEMI
patients and those with a symptom onset to treatment
time of 4 to 6 h had a >40% relative increase in mor-
tality at 30 days when compared with patients with
shorter treatment times (18). Increases in MVO and
myocardial hemorrhage in patients with a prolonged
ischemic time treated with thrombolysis may be a
contributing factor for this increase in mortality. This
could be considered by clinicians when a choice is
available between prompt thrombolysis and delayed
PCI beyond the guideline-directed 120-min target in
patients with prolonged ischemic times.
STUDY LIMITATIONS. First, the study was dis-
continued when pre-specified futility criteria were
met. The objectives of this phase 2 trial included evi-
dence synthesis for mechanisms evaluation as well as
efficacy. To an extent, premature discontinuation
limits mechanism evaluation. Second, although
ischemic time was a pre-specified subgroup, no
adjustment for multiplicity was made in this subgroup
analysis. Finally, the decision to explore treatment
effects as trends across treatment groups was made
post hoc, this provided stronger evidence of the
interaction based on ischemic time and treatment withalteplase. The results of this analysis should therefore
be interpreted as exploratory and not definitive.
CONCLUSIONS
In patients presenting with acute STEMI and an
ischemic time $4 to 6 h, adjunctive, low-dose,
intracoronary alteplase given during PPCI may in-
crease MVO and myocardial hemorrhage and reduce
left ventricular ejection fraction. The mechanisms
may involve hemorrhagic transformation within the
infarct core. The results do not support administering
intracoronary alteplase in patients with STEMI pre-
senting with an ischemic time $4 to 6 h.
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PERSPECTIVES
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: In patients with acute STEMI
and an ischemic time $4 to 6 h undergoing PPCI, low-
dose intracoronary alteplase increases MVO and myocar-
dial hemorrhage and worsens left ventricular function.
TRANSLATIONAL OUTLOOK: Future studies of
intracoronary thrombolysis should focus on patients
presenting within 4 h of symptom onset.
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